Phase II/III study of novel COVID-19 oral treatment Paxlovid, is initiated in pediatric participants.- Pfizer
Pfizer Inc. announced that it has initiated a Phase II/III study, EPIC-PEDS (Evaluation of Protease Inhibition for COVID-19 in Pediatric Patients), to evaluate the safety, pharmacokinetics, and efficacy of Paxlovid (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) in non-hospitalized, symptomatic, pediatric participants with a confirmed diagnosis of COVID-19 who are at risk of progression to severe disease.